AACR postpones April meeting over COVID-19 concerns
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
The American Association for Cancer Research has postponed its April meeting, one of the largest medical meetings so far to be canceled due to the COVID-19 outbreak.
For AACR, meetings and workshops represent about one quarter of the revenue, but the annual meeting is a flagship event, and has grown from an important research conference to a major item on biotech’s oncology calendar, arguably matching ASCO (see “Hidden Consequences of COVID-19”).
AACR said it expects to reschedule the meeting, which had been set for April 24-29 in San Diego, in the near future. At least 21 other healthcare conferences have been affected by the COVID-19 outbreak, including cancellations, reschedulings and options to attend virtually (see “COVID-19: A Guide to Conferences”).
“This evidence-based decision was made after a thorough review and discussion of all factors impacting the Annual Meeting, including the U.S. government’s enforcement of restrictions on international travelers to enter the U.S.; the imposition of travel restrictions issued by U.S. government agencies, cancer centers, academic institutions, and pharmaceutical and biotech companies and the counsel of infectious disease experts,” AACR said in a statement.
In 2003, the organization canceled its meeting during the SARS crisis.
The postponement comes after Bio-Europe Spring announced that its Paris meeting this month will be held virtually (see “Bio-Europe Spring will be First Test for Virtual Partnering”).
Further analysis of the coronavirus crisis can be found at https://www.biocentury.com/coronavirus.